The company has decided to discontinue its stem cell trial for spinal cord injury patients in an effort to focus on its oncology program. The change comes in part because of the uncertain economic climate in the United States, as eliminating efforts on the spinal cord injury program will allow the company enough resources to develop oncology drugs that are currently in Phase II clinical trials.
While the company has closed the spinal cord injury trial to future enrollment, it will continue to follow all enrolled patients and update the FDA and medical community on trial data. To this point, none of the four enrolled patients have experienced adverse effects.
Sign up for our FREE Spine E-Weekly for more coverage like this sent to your inbox!
Related Articles on Spinal Cord Injury:
A New Hope for Treating Spinal Cord Injury: 5 Points on InVivo Therpeutics’ Technology
Restoring Function After Spinal Cord Injury With Nerve Transplant: The New Frontier
Paralyzed Patient Regains Some Motion After Electrical Spinal Cord Stimulation
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.